Skip to main content

Table 3 Neoadjuvant treatment-emergent adverse events (safety set, n = 32)

From: Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Adverse event Any grade Grades 1–2 Grade 3 Grade 4
Thrombocytopenia, n (%) 16 (50.0%) 9 (28.1%) 4 (12.5%) 3 (9.4%)
Hypertension, n (%) 14 (43.8%) 5 (15.6%) 9 (28.1%) 0
Neutropenia, n (%) 12 (37.5%) 7 (21.9%) 4 (12.5%) 1 (3.1%)
Leukopenia, n (%) 11 (34.4%) 11 (34.4%) 0 0
Anorexia, n (%) 10 (31.4%) 7 (21.9%) 3 (9.4%) 0
Proteinuria, n (%) 9 (28.1%) 8 (25.0%) 1 (3.1%) 0
Anemia, n (%) 8 (25.0%) 8 (25.0%) 0 0
Fatigue, n (%) 7 (21.9%) 4 (12.5%) 3 (9.4%) 0
Oral mucositis, n (%) 6 (18.8%) 6 (18.8%) 0 0
Vomiting, n (%) 5 (15.6%) 5 (15.6%) 0 0
Hand-foot syndrome, n (%) 2 (6.3%) 1(3.1%) 1 (3.1%) 0
Elevation of ALT/AST, n (%) 2 (6.3%) 2 (6.3%) 0 0
Tumor bleeding, n (%) 1 (3.1%) 0 0 1 (3.1%)
  1. ALT alanine aminotransferase, AST aspartate aminotransferase. Any grade adverse events occurring in > 5% of patients and all grade 3 or 4 adverse events were listed. No grade 5 adverse events occurred